# AOD-9604: Research Overview — Private Peptides > A clinical-briefing read on AOD-9604, the tyrosine-substituted hGH fragment 176-191: mechanism, the preclinical fat-metabolism record, the human obesity trials, and the documented cautions. A 16-amino-acid piece of human growth hormone, engineered to keep the fat-metabolizing signal and drop the growth-promoting one — strong in rodents, unproven in the pivotal human obesity trials. ## The short version AOD-9604 is a lab-made **hexadecapeptide** — a chain of 16 amino acids — copied from the tail end of human growth hormone (hGH), the piece known to drive fat metabolism, with one amino acid swapped out to make it easier to manufacture. The idea behind it: keep the fat-burning signal of hGH, drop the growth-promoting and blood-sugar-raising effects that make full-length hGH unsuitable as a casual weight-loss agent. In rodent studies, it inhibited fat *synthesis* and increased fat *burning*, working through a receptor separate from the growth-hormone receptor [4][6][7]. In non-clinical toxicology, it looked clean — no genotoxic signal, a very short circulating half-life of about three minutes after IV dosing [2]. Across roughly six human trials in about 900 obese adults, it was as well tolerated as placebo [3] — but tolerability is not the same as efficacy, and the pivotal human weight-loss program did not clear that second bar. This page reports the mechanism, the record, and the gap between them. It lists no dose as a recommendation. ## What it is AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide modeled on residues 177-191 of human growth hormone — the hormone's C-terminal, fat-metabolism domain — with an N-terminal tyrosine substituted for the native phenylalanine to aid synthesis and stability. Two cysteine residues form an intramolecular disulfide bridge that mirrors the cystine loop of the parent hormone. Reported sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. The design logic is subtractive: full-length hGH does far more than burn fat — it drives linear growth, raises IGF-1, and can worsen insulin resistance. AOD-9604 isolates the fragment of the molecule associated with fat metabolism and removes the rest, at least in principle. It does not bind the growth hormone receptor, which is the structural basis for the claim that it avoids GH's growth-axis side effects [7]. ## How it works Two mechanisms are documented. First, AOD-9604 inhibits acetyl-CoA carboxylase (ACC), the enzyme that commits fatty acids to storage — original work traced this to an interaction with adipocyte and hepatocyte cell membranes that releases a second messenger, increasing ACC phosphorylation and shutting the enzyme down [7]. Blocking ACC slows new fat synthesis (lipogenesis) rather than directly "melting" existing fat. Second, chronic dosing in obese mice increased expression of the beta-3 adrenergic receptor (beta3-AR) in white adipose tissue, and the chronic weight- and fat-reducing effect disappeared entirely in beta3-AR knockout mice — while an acute rise in energy expenditure and fat oxidation persisted even without the receptor, pointing to at least two separable pathways [4]. A parallel study confirmed the C-terminal fragment increased fat oxidation and reduced weight in obese mice in a direction comparable to full-length hGH [5], and earlier metabolic work had already localized hGH's antilipogenic activity to this same C-terminal domain [6]. None of this engages the GH receptor, which is the mechanistic basis for AOD-9604 being marketed as growth-axis-neutral. ## What the research shows *Preclinical fat metabolism.* In obese mice, 14 days of chronic dosing reduced body weight and fat and raised beta3-AR expression; the effect required a functional beta3-AR (it vanished in knockout mice), while acute fat-oxidation and energy-expenditure changes did not require the receptor [4]. A related study in obese mice found the same direction of effect — increased fat oxidation, reduced weight — with the fragment as with intact hGH [5]. Metabolic characterization work in the 1980s and 2000s established the underlying enzymatic mechanism (ACC inhibition via a membrane second messenger) [7] and confirmed the C-terminal region as the functional lipolytic/antilipogenic domain of hGH [6]. *Non-clinical safety and pharmacokinetics.* A non-clinical evaluation across rats and primates found no genotoxic or toxicological concern with chronic administration, including oral dosing. Intravenous pharmacokinetics showed a very short circulating half-life — about three minutes — with degradation proceeding by sequential removal of N-terminal amino acids; oral absorption was separately demonstrated in a pig model [2]. *Human trials.* Across roughly six clinical trials totaling about 900 obese adults, oral AOD-9604 at daily doses from 0.25 mg to 54 mg, over durations from 7 days to 24 weeks, produced a safety and tolerability profile indistinguishable from placebo, without the adverse effects associated with full-length hGH [3]. The trial program's primary weight-loss endpoint, however, did not separate AOD-9604 from placebo at a statistically significant level, and the obesity development program was discontinued around 2007 — a result the tolerability data do not change. *A separate line of work* has tested AOD-9604 by intra-articular injection in a rabbit model of collagenase-induced knee osteoarthritis, where weekly dosing (with or without hyaluronic acid) reduced cartilage-degeneration scores versus saline over 4-7 weeks [1]. This is a preclinical joint-health signal, unrelated to the weight-loss question and not yet tested in human osteoarthritis. ## Reported effects, cautions & safety People discussing AOD-9604 in fat-loss and biohacking communities describe a consistent pattern. These reports are **anecdotal, not clinical evidence** — self-reported, unverified, and not a substitute for the trial record above. *Reported benefits (anecdotal, not clinical evidence):* Most commonly, people describe it as easy to tolerate, without the water retention, joint puffiness, or tingling some associate with growth-hormone-elevating protocols. A minority note a mild lift in energy or a modest sense of reduced appetite. Where visible change is reported at all, it is almost always credited to a concurrent calorie deficit and training program running in parallel, not to the peptide alone. *Reported adverse effects and disappointments (anecdotal, not clinical evidence):* The single most common report is the least flattering one — no noticeable fat loss, a pattern that lines up with the human trial record rather than contradicting it. Occasional injection-site redness or itching that settles on its own is mentioned. Claims of localized or 'spot' fat loss near the injection site circulate in forums but are not biologically supported — no human trial of any injected peptide has shown site-specific fat loss. Long-time users and clinician commentary both describe a recurring theme of disappointment relative to marketing claims for this compound. *What to watch — cited cautions from the literature:* - **Mechanism is largely preclinical and indirect.** ACC inhibition, beta3-AR upregulation, and increased fat oxidation were characterized chiefly in mouse, rat, and cell-membrane systems; these findings have not translated into a demonstrated human fat-loss effect [6]. - **Animal efficacy did not translate to humans.** Chronic dosing reduced weight and fat in obese mice and required intact beta3-AR signaling to do so, but the same benefit was not established in the human obesity program [4]. - **Investigational status.** AOD-9604 was developed as an anti-obesity drug candidate and never received marketing approval from any regulator; there is no approved dose, formulation, or manufacturing quality standard. - **Human weight-loss efficacy was not demonstrated.** The pivotal obesity trial program did not separate from placebo on the primary weight-loss endpoint, and development was discontinued. - **Long-term human safety data are limited.** Published human exposure tops out around 24 weeks; there is no long-term or large-scale safety surveillance beyond that window. - **Regulatory and anti-doping status shift.** AOD-9604 was reviewed by the FDA Pharmacy Compounding Advisory Committee in December 2024 regarding 503A compounding eligibility, and current status should be independently verified; as a growth-hormone fragment, it is prohibited at all times in sport under the WADA Prohibited List, Section S2, and is detectable by dedicated assays. ## Where it fits in Metabolic & Weight Research AOD-9604 anchors the fragment end of this desk's frame: a small, narrowly targeted piece of a natural hormone, with a mechanism proven in rodents and cells but not confirmed in the human obesity trials that mattered most. [MOTS-c](/mots-c) moves the frame toward endogenous cellular signaling — a peptide the mitochondria already make, acting on an energy-sensing switch rather than a single adipose pathway. [Retatrutide](/retatrutide) moves it further still, toward a fully engineered molecule built to hit three receptors deliberately. Reading AOD-9604 first sets the baseline question this desk keeps asking: does a promising preclinical mechanism survive contact with a human trial? See the [comparison page](/compare) for how the three answer that question differently. ![AOD-9604 research illustration — abstract lipolytic pathway motifs in magenta](/images/aod-9604.webp) --- Private Peptides is filed like a clinician's briefing, not a chart note: evidence in, strength labeled, and no dose is ever recommended.